*僅供醫學專業人士閱讀參考

形態、標志物與分子特征協同，助力epNEC診療邁向精準診療新階段

*以下內容僅供醫療衛生專業人士瀏覽。

參考文獻：

[1]Rindi G, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms[J]. Endocrine pathology, 2022, 33(1): 115-154.

[2]Dasari A, et al. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases[J]. Cancer, 2018, 124(4): 807-815.

[3]Zeng X, et al. The challenge of diagnosing neuroendocrine neoplasms: experience from a national reference center[J]. Virchows Archiv, 2024: 1-11.

[4]中國臨床腫瘤學會指南工作委員會. 中國臨床腫瘤學會（CSCO）神經內分泌腫瘤診療指南 2024[M]. 北京 ：人民衛生出版社， 2024.

[5]Centonze G, Maisonneuve P, Prinzi N, et al. Prognostic factors across poorly differentiated neuroendocrine neoplasms: a pooled analysis[J]. Neuroendocrinology, 2023, 113(4): 457-469.

[6]Lozada J R, et al. Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting[J]. Cancer Research Communications, 2025, 5(2): 318-326.

SC-CN-17834

*此文僅用于向醫療衛生專業人士提供科學信息，不代表平臺立場。